Charles Ryan

Charles S.
Ryan is Chief Executive Officer at Quince Therapeutics SpA since 2023.
Holds director positions at GlycoMira LLC, Polaryx Therapeutics, Inc. starting 2026, and is a member of the New York State Bar Association.
Serves as President of Quince Therapeutics, Inc. since 2023 and trustee at The College of Wooster.
Formerly served as President, Chief Executive Officer & Director at Orthobond Corp.
from 2016 to 2018.
Chief Executive Officer & Director at Neurotrope, Inc. from 2018 to 2020.
Chief Executive Officer & Director at TAO Synergies, Inc. from 2018 to 2020.
Chief Executive Officer & Director at Petros Pharmaceuticals, Inc. Chairman, President & Chief Executive Officer at Travecta Therapeutics Pte Ltd. from 2017 to 2022.
Chairman-Development Council at Stony Brook University Medical Center.
Independent Director at BNB Plus Corp.
from 2011 to 2019.
Director at New York Biotechnology Association, Inc. Independent Director at BioRestorative Therapies, Inc. from 2015 to 2020.
Director at ABS Materials, Inc. and GlycoMira Therapeutics, Inc. Chief Intellectual Property Counsel & Senior VP at Forest Laboratories, Inc. from 2003 to 2014.
Vice President & General Counsel at Engelhard Long Island, Inc. from 1998 to 2002.
Trustee at Western New England University.
Chief Operating Officer at LAB21, Inc. from 2002 to 2003.
Vice President & General Counsel at Cold Spring Harbor Laboratory, Inc. from 2015 to 2016.
Education includes a doctorate from Stony Brook University in 1990, a graduate degree from Western New England University School of Law in 1993, and an undergraduate degree from The College of Wooster in 1986.